



Episurf Medical provides COVID-19 related update ahead of investor conference

Episurf Medical (Nasdaq: EPISB) today provides updates regarding the business activity during Q1 2021, reflecting impacts from the current pandemic. When it issued its Q4 2020 report, published on February 19th, the company indicated low business volumes resulting from pandemic-related restrictions. However, the company can now report that it is experiencing double-digit growth in gross order intake in Q1 2021 compared to Q1 2020. Furthermore, the company has seen a 45% increase in the number of active customers during the quarter.

"These are challenging times, of course, but we are continuing to take the right steps in our early commercialization in Europe, and, if anything, we are progressing slightly better than expected during Q1 2021 against the headwinds of COVID-19-related restrictions in our markets. I am particularly happy about the strong growth in the number of active customers, as building a large global base of repeat customers is at the core of our strategy", says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel: +46 (0) 709 62 36 69
Email: [pal.ryfors@episurf.com](mailto:p.al.ryfors@episurf.com)

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's µiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 09.45 CET on 24 March, 2021.